OPPS Pro-Rata Reduction Data, Policy Options Weighed By AdvaMed/PhRMA
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed will collaborate with the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Association in reviewing Medicare data that HCFA may use to implement a pro-rata reduction of OPPS payments in 2002.
You may also be interested in...
Medicare Proposal Lacks Cost Data, Imposes Limitations On Industry Rebuttal
CMS' omission of cost-and-utilization data related to its hospital outpatient prospective system (OPPS) proposal makes it difficult for device manufacturers to bolster their arguments against a pro-rata reduction.
Medicare Proposal Lacks Cost Data, Imposes Limitations On Industry Rebuttal
CMS' omission of cost-and-utilization data related to its hospital outpatient prospective system (OPPS) proposal makes it difficult for device manufacturers to bolster their arguments against a pro-rata reduction.
OPPS Proposal Delayed As 70% Pro-Rata Reduction Finds Critics On The Hill
A pro-rata reduction exceeding 70% in Medicare "pass-through" payments, expected to be included in CMS' outpatient prospective payment system (OPPS) proposed rule, is preventing timely release of the document.